09/10/2026 Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO Alumis reported new Phase 3 data for envudeucitinib in plaque PsO Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO (Ref) Johnson & Johnson reported 2-year Phase 3, ICONIC-LEAD/ NCT06095115 data for ICOTYDE® (icotrokinra; IL-23 receptor antagonist) in patients aged ≥12 years with moderate-to-severe plaque psoriasis (PsO).  Endpoint Results Timepoint PASI 90 ≥72% At Wk 12 IGA 0/

01/09/2026 Novartis’s remibrutinib significantly reduced relapse rates and demonstrated a favourable safety profile in Ph3 RMS trials. Adicet Bio announced completion of the last patient visit for the planned analysis of prula-cel study in patients with SLE with or without LN. Alumis announced topline results from the Ph2b trail of envudeucitinib in SLE. Novartis’s remibrutinib significantly reduced relapse rates and demonstrated a favourable safety profile in Ph3 RMS trials.

27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa